A year ago this week, Connecticut Attorney General William Tong announced that the state would settle one of its longest-running and most-contentious lawsuits. Today, the state still awaits the tens of millions of dollars that would be provided by that resolution.

The wait goes on because of Stamford-based Purdue Pharma’s ongoing bankruptcy — a deeply complex and acrimonious process, started three-and-a-half years ago, that aims to settle several thousand lawsuits accusing the company of fueling the national opioid crisis with deceptive marketing of its OxyContin pain drug. But Connecticut does not rely solely on Purdue for funding because its share of multibillion-dollar settlements with other pharmaceutical companies is already helping to tackle an unrelenting epidemic that has taken thousands of lives in the state in recent years.

“The way I think about Purdue is in the context of all our work in fighting the opioid-and-addiction crisis and addiction industry,” Tong said in an interview. “I don’t think of any one case apart from the others. It’s all part of one giant effort to seek justice for victims and survivors and find resources to fund treatment, prevention and addiction science.”